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Introduction: Studies with mesenchymal stem cells (MSCs) are increasing due to their immunomodulatory,
anti-inflammatory and tissue regenerative properties. However, there is still no agreement about the best source of
equine MSCs for a bank for allogeneic therapy. The aim of this study was to evaluate the cell culture and
immunophenotypic characteristics and differentiation potential of equine MSCs from bone marrow (BM-MSCs),
adipose tissue (AT-MSCs) and umbilical cord (UC-MSCs) under identical in vitro conditions, to compare these sources
for research or an allogeneic therapy cell bank.
Methods: The BM-MSCs, AT-MSCs and UC-MSCs were cultured and evaluated in vitro for their osteogenic, adipogenic
and chondrogenic differentiation potential. Additionally, MSCs were assessed for CD105, CD44, CD34, CD90 and MHC-II
markers by flow cytometry, and MHC-II was also assessed by immunocytochemistry. To interpret the flow
cytometry results, statistical analysis was performed using ANOVA.
Results: The harvesting and culturing procedures of BM-MSCs, AT-MSCs and UC-MSCs were feasible, with an
average cell growth until the third passage of 25 days for BM-MSCs, 15 days for AT-MSCs and 26 days for UC-MSCs.
MSCs from all sources were able to differentiate into osteogenic (after 10 days for BM-MSCs and AT-MSCs and
15 days for UC-MSCs), adipogenic (after 8 days for BM-MSCs and AT-MSCs and 15 days for UC-MSCs) and chondrogenic
(after 21 days for BM-MSCs, AT-MSCs and UC-MSCs) lineages. MSCs showed high expression of CD105, CD44 and
CD90 and low or negative expression of CD34 and MHC-II. The MHC-II was not detected by immunocytochemistry
techniques in any of the MSCs studied.
Conclusions: The BM, AT and UC are feasible sources for harvesting equine MSCs, and their immunophenotypic
and multipotency characteristics attained minimal criteria for defining MSCs. Due to the low expression of MHC-II
by MSCs, all of the sources could be used in clinical trials involving allogeneic therapy in horses. However,
the BM-MSCs and AT-MSCs showed fastest ‘‘in vitro’’ differentiation and AT-MSCs showed highest cell growth until
third passage. These findings suggest that BM and AT may be preferable for cell banking purposes.* Correspondence: rmamorim@fmvz.unesp.br
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Mesenchymal stem cells (MSCs) are non-hematopoietic,
multipotent progenitor cells that are easily isolated from
various adult tissues. MSCs are characterized by extensive
proliferative ability, as well as the ability to differentiate
in vitro into various mesenchymal lineages in response
to an appropriate stimulus. These lineages include oste-
oblasts, adipocytes, chondrocytes, tenocytes and myo-
cytes [1,2]. The use of MSCs has been demonstrated in
the cartilage, bone and tendon of horses [3-5]. Although
controversial, MSCs can also differentiate in response
to specific stimuli in germ cells of other lineages, such
as neurons, glial cells and hepatocytes [6-8].
In equine species, bone marrow (BM) is one of the most
studied and used sources for obtaining adult stem cells
[9,10]. However, adipose tissue (AT) is also an abundant
and accessible source of MSCs that can provide a large
number of cells required for use in cell therapy [11,12].
Additionally, cells from the amniotic membrane [13]
and umbilical cord (UC) are a promising source of MSCs
because they are less immunogenic, their collection is
non-invasive, and they have the potential to differentiate
into neural and endothelial cells [14,15].
Equine MSCs are mainly identified by their adherence
to plastic and their ability to differentiate into multiple
lineages [16] because immunophenotyping in horses is
hindered by the lack of specific markers, limited avail-
ability of monoclonal anti-horse antibodies [17-19] and
evidence that certain markers of other species do not
cross-react with equine species [11]. Therefore, several
markers have been tested and used, such as the positive
markers CD44, CD90 CD29 [11,15,17,20], CD105 [21-23],
MHC-I [5,15,20] and the negative markers CD14
[17], CD34 [21,23], MHC-II [5,17,20,23,24], CD45
[21,24], based on minimal criteria established by the
International Society for Cellular Therapy (ISCT) to
define human MSCs [25] and adipose-tissue derived
stromal/stem cells [26].
Evidence suggests that these cells improve regeneration
and tissue function by their ability to self-renew [3], their
ability to differentiate into mesodermal, neuroectodermal
and endodermal lineages [6], their synthesis of growth
factors and their release of anti-inflammatory and im-
munomodulatory cytokines [2,18,20,27].
Autologous therapy with MSCs is widely used because
it does not result in any significant deleterious effects at
the time of implantation or later [28], and shows anti-
inflammatory and immunosuppressive effects [29]. How-
ever, treatment with autologous MSCs has limitations,
such as in acute injuries, because expansion of MSCs by
culturing takes 10 to 21 days [5], or in elderly patients
because there is a decrease in the quantity, proliferation
and differentiation potential of MSCs [30]. Nevertheless,
adipose-derived nucleated cells have a short interval forisolation of an injectable uncultured cell pool (24 to
48 hours), providing distinct advantages with regard to
timeliness compared with an injection of cultured MSCs
from other sources [29,31].
Allogeneic treatment in horses offers advantages in
acute injuries because MSCs can be injected quickly.
Allogeneic treatment then eliminates the time needed
for the isolation and expansion of autologous MSCs.
This treatment also allows the use of a more homoge-
neous cell population with a proven capacity for differenti-
ation into various lineages [5,18,31], by taking MSCs from
a cell bank of horse donors [27,32]. However, a heteroge-
neous cell population can be more effective depending on
the disease, as shown by Semon et al. [31], where stromal
vascular fraction, which is composed of a heterogeneous
mixture of cells, effectively inhibited experimental auto-
immune encephalomyelitis disease progression in mice
more than culture-expanded adipose derived stromal
cells.
The lack of expression of the major histocompatibil-
ity complex class II (MHC-II) on the cell surface is an
important immunomodulatory characteristic. This lack
of expression gives MSCs the potential to escape from
T-cell recognition [33], making it feasible to create a cell
bank for use in allogeneic therapies [5,10,18,31].
In the present study, we assessed the differences in cell
culture; immunophenotypic characterization with CD44,
CD90, CD105, CD34 and MHC-II markers; and the differ-
entiation potential of MSCs from equine bone marrow
(BM-MSCs), adipose tissue (AT-MSCs) and umbilical cord
tissue (UC-MSCs) aiming to compare these sources for
research or an allogeneic therapy cell bank. For our
knowledge, there is a lack of data comparing these char-
acteristics (cell culture, CD expression and differenti-
ation potential) from equine BM-, AT- and UC-MSCs at
the same time and under identical in vitro conditions.
Methods
Animal ethics
All stages of this study were conducted in accordance
with the Ethical Principles in Animal Experimentation
and were approved by the Ethics Committee on Animal
Use of São Paulo State University (UNESP) - Botucatu
(Protocol 178/2011-CEUA).
Study design
Ten clinically healthy crossbred horses of both sexes,
ranging in age from 6 to 13 years old, were randomly
assigned to two groups for the harvest of bone marrow
(n = 5) or adipose tissue (n = 5). To obtain the umbilical
cord (n = 6), two samples were collected from two births
and four samples from the slaughter of horses. MSCs
were cultured, and on the third passage (P3), they were
assessed using immunophenotypic characterization by
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for their differentiation potential into three mesenchy-
mal lineages.
Mesenchymal stem cell collection and isolation
Bone marrow
The collection and isolation of BM-MSCs were per-
formed by aspiration of the bone marrow according to
the methodology described by Maia et al. [34] with some
modifications.
Five animals (n = 5), ranging in age between 7 and
12 years, were sedated with intravenous xylazine hydro-
chloride 10% (0.5 mg/kg) (Sedomin, König, Avellaneda,
Buenos Aires, Argentina). A local anesthetic block was then
performed with 2% lidocaine hydrochloride (Xylestesin,
Cristália, Sao Paulo, Brazil) in the region of the fifth
sternebrae, where bone marrow cells were collected with
a Komiyashiki® needle. Two syringes containing 2 mL of
1,000 IU/mL heparin (Hemofol, Cristália, São Paulo, Brazil)
and 2 mL of Hanks’ Balanced Salt Solution (HBSS, Invitro-
gen, Grand Island, New York, USA) were used for the
bone marrow collection. The samples (a total of 40 mL per
animal) were centrifuged at 340 × g for 10 minutes, and
the supernatant was discarded. DMEM low glucose/F12
(Invitrogen, Grand Island, New York, USA) was added to
the remaining material at a ratio of 1:1, and this mixture
was slowly added to Histopaque-1077 (Sigma-Aldrich
Corp., St. Louis, Missouri, USA) at a ratio of 1:1,
followed by further centrifugation at 340 × g for 40 mi-
nutes. After obtaining the mononuclear fraction, DMEM
low glucose/F12 1:1 was added, and the sample was cen-
trifuged twice at 340 × g for 10 minutes. The cell number
was determined using the Trypan Blue exclusion method.
Cells were cultured at a density of approximately 10 × 103
cells/cm2 in 25-cm2 flasks (Sarstedt, Newton, North
Carolina, USA) containing a culture medium consisting
of 80% DMEM low glucose/F12 (1:1), 20% fetal bovine
serum (Invitrogen, USA), 1% penicillin/streptomycin
(Invitrogen, USA) and 1.2% amphotericin B (Invitrogen,
USA) at 37°C in a humidified atmosphere containing 95%
air and 5% CO2. The culture medium was changed every
three days until a cell confluence of ≥80% was reached.
Adipose tissue
The collection of adipose tissue was performed in the
region above the dorsal gluteal muscle (tail base) as de-
scribed by Carvalho et al. [11]. The animals (n = 5), ran-
ging in age between 6 and 13 years, were sedated
intravenously with xylazine 10% (0.5 mg/kg) (Sedomin,
König, Argentina) followed by an inverted L-block of local
anesthetic using 2% lidocaine hydrochloride (Xylestesin,
Cristália, Brazil).
Approximately 1 g of adipose tissue was collected and
stored for 20 minutes, until arrival at the laboratory, atroom temperature in a sterile 50 mL conical tube contain-
ing HBSS solution plus 2% penicillin/streptomycin.
The adipose tissue sample was washed three times with
HBSS/penicillin, submitted to mechanical separation using
a scalpel and anatomical forceps to approximately 0.2 to
0.3 cm size and then placed in a solution of 0.04% type 1
collagenase (Invitrogen, USA) at 37°C for 30 minutes.
After this period, the solution was filtered through a 70-
micrometer filter, DMEM low glucose (1:1) was added,
and the solution was centrifuged twice at 340 × g for
15 minutes. A sample of cells was stained with Trypan
Blue and counted using a microscope counting cham-
ber. Cells were cultured at a density of approximately
10 × 103 cells/cm2 in 25-cm2 flasks containing the culture
medium described previously at 37°C in a humidified at-
mosphere containing 95% air and 5% CO2. The culture
medium was changed every three days until a cell conflu-
ence of ≥80% was reached.
Umbilical cord
For samples from births, approximately 10 cm of umbilical
cord from the fetal portion was collected immediately
after delivery (n = 2) and stored in a sterile 50 mL conical
tube containing HBSS plus 2% penicillin/streptomycin.
For samples from slaughterhouses (n = 4), during eviscer-
ation pregnant uteri were separated, opened and a sample
of 10 cm from the umbilical cord from the fetal portion
was collected. Fetuses ranging in age from 9 (n = 2) to
10 (n = 2) months were used.
Umbilical cord samples were washed three times in
HBSS/penicillin and submitted to mechanical dissection
to separate veins and arteries, which were discarded. The
umbilical cord tissue (perivascular region) was fragmented
using a scalpel and anatomical forceps to approximately
0.2 to 0.3 cm in size and then placed in a 0.04% solution
of type 1 collagenase (Invitrogen, USA) at 37°C for
60 minutes. The sample was then processed as described
for the adipose tissue, with the exception of a culture
medium containing DMEM high glucose (Invitrogen,
USA) as described by Corradetti et al. [35].
The trypsinization of the cells was accomplished when
a confluence of ≥80% was reached. For this step, 0.25%
trypsin (Invitrogen, USA) was added at 37°C for five mi-
nutes. The cell suspension was centrifuged twice at 340 × g
for 10 minutes to remove the trypsin. Subsequently, the
cell pellet was resuspended in culture medium, and this
volume was divided into two 25-cm2 flasks. Cells were cul-
tured under the same conditions as described above.
Osteogenic, chondrogenic and adipogenic differentiation
of MSCs
During the third passage (P3), BM-MSC, AT-MSC and
UC-MSC samples were placed in triplicate in six-well
plates (Sarstedt, USA) for osteogenic and adipogenic
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fied atmosphere containing 95% air and 5% CO2. After
reaching 80% confluence, the culture medium was re-
moved and the differentiation media StemPro adipogen-
esis and StemPro osteogenesis (Invitrogen, USA) were
added to the cultures. The media were changed every
three days, and adipogenic differentiation was confirmed
by the deposition of lipid droplets in the cytoplasm using
0.5% Oil Red O staining (Sigma-Aldrich Corp., USA). The
osteogenic differentiation was confirmed by positive stain-
ing of the extracellular calcium matrix using 2% Alizarin
Red S staining (Sigma-Aldrich Corp., USA).
For chondrogenic differentiation, a pellet of MSCs was
cultured in a Falcon tube and incubated at 37°C in a
humidified atmosphere containing 95% air and 5% CO2.
After two days, the culture medium was removed and
the differentiation medium StemPro chondrogenesis
(Invitrogen, USA) was added and changed every three
days. To confirm chondrogenic differentiation, pellets
were stained with Alcian Blue (pH = 2.5) and toluidine
blue (pH = 1) to identify proteoglycans.
MSC characterization
Flow cytometry
Immunophenotypic analysis of BM-MSCs, AT-MSCs and
UC-MSCs was performed at P3 with the FACS Calibur
flow cytometer (BD, Franklin Lakes, NJ, USA) using the
following antibodies: mouse anti-rat CD90-FITC (clone
OX7, Caltag Laboratories, Burlingame, California, USA),
mouse anti-human CD34-FITC (clone 581, BD, USA),
mouse anti-human CD105-FITC (clone SN6, Abcam,
San Francisco, California, USA), mouse anti-horse CD44
(clone CVS18, AbD Serotec, Kidlington, Oxfordshire, UK)
and mouse anti-horse MHC class II monomorphic (clone
CVS20, AbD Serotec, UK). For the unconjugated primary
markers, the secondary antibody goat anti-mouse IgG-
FITC (AbD Serotec, UK) was used. The protocols used
were those described by the manufacturers.
Immunocytochemistry for MHC-II
Samples at P3 were plated in 24-well plates (Sarstedt,
USA). After 80% confluence was reached, the cells were
fixed and permeabilized with Cytofix/Cytoperm™ (BD,
USA), and then an endogenous peroxidase block was
conducted for 20 minutes. After this period, the samples
were incubated for one hour in a 3% milk powder solu-
tion for nonspecific protein blocking. Then, the primary
antibody mouse anti-horse MHC class II monomorphic
(clone CVS20, Abd Serotec, UK) and negative control IgG
anti-mouse (Dako Cytomation, Glostrup, Denmark) were
incubated in the dark for 18 hours at 4°C. The primary
antibodies were detected by incubating with the polymer
system HiDef HRP mouse/rabbit Polymer Detection Sys-
tem (Cell Marque, Rocklin, CA, USA). The developmentreaction was conducted using the chromogenic substrate
DAB solution (Dako Cytomation, Denmark) for five mi-
nutes, followed by counterstaining with Harris Hematoxylin
(Merck, Rockland, Massachusetts, USA) for one minute.
The evaluation of the reaction was performed using an
inverted light microscope (Leica Microsystems, Wetzlar,
Germany).
The positive control was performed for MHC-II anti-
body using a horse muscle tissue sample.
Statistical analysis
For the statistical analysis, the binomial dependent vari-
ables (positive marker percentage of CD105, CD90, CD44,
CD34 and MHC-II) were evaluated with an ANOVA using
the General Linear Model (GLM) procedure with the SAS
statistical software package (SAS, Inst., Inc., Cary, NC,
USA). Sources of variation in the model included cellular
source (UC, BM or AT) and animals, which were consid-
ered as fixed and random effects, respectively. The arcsine
transformation was applied to the percentage of data to
improve normality. If the ANOVA was significant, means
were separated using the least significant difference (LSD).
The data are reported as the least-squares means ± SEM.
For all analyses, a significance level of 5% was used.
Results
Cell culture
All of the MSCs cultured from BM, AT and UC adhered
to the flasks in the first days of culture. Adhesion of
MSCs to the plastic flask was observed within 48 hours
for BM-MSCs, 32 hours for AT-MSCs and 48 hours for
UC-MSCs.
Early fibroblastoid morphology in MSCs was visualized
with an average of 4.5 ± 0.70 days of culture for MSCs
from BM, 3.5 ± 2.12 days for MSCs from AT and 4.8 ±
1.30 days for MSCs from UC.
The time to reach approximately 80% cell confluence
differed between the samples: 11 days for BM-MSCs,
7.3 ± 1.52 days for AT-MSCs and 15.25 ± 6.65 days for
UC-MSCs (Figure 1). After the first passage, 80% conflu-
ence was achieved with an average of 5.2 ± 1.64 days for
BM-MSCs, 3.2 ± 0.44 days for AT-MSCs and 6.16 ±
2.40 days for UC-MSCs.
The time from primary culture until the third passage,
when characterization and cell differentiation was per-
formed, was an average of 25 ± 3.93 days for BM-MSCs,
15.5 ± 0.70 days for AT-MSCs and 26.75 ± 7.22 days for
UC-MSCs.
Potential of differentiation into mesodermal lineages
The in vitro differentiation potential of BM- and AT-
MSCs for osteogenic and adipogenic lineages was shown
after the 10th and 8th days, respectively. The UC-MSCs
did not differentiate in this time interval, requiring new
Figure 1 MSCs from BM, AT and UC during cell culture
showing ≥80% confluence. MSCs from BM (A), AT (B) and UC
(C) with approximately 80% confluence after 11, 7 and 15 days of
culture, respectively. (A) and (B) 100x magnification and (C) 200x
magnification. AT, adipose tissue; BM, bone marrow; MSCs,
mesenchymal stem cells; UC, umbilical cord.
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cytes and adipocytes was observed only after 15 days in
these cells.
The osteogenic differentiation was confirmed by posi-
tive staining of the calcium matrix by Alizarin Red dye.
Additionally, a change from fibroblastoid morphologyto a predominantly polygonal morphology in a large
proportion of the cells was observed (Figure 2). The dif-
ferentiation into adipose tissue was confirmed by the
deposition of lipid droplets into the cytoplasm, as visu-
alized by Oil Red staining (Figure 2).
The chondrogenic differentiation occurred after 21 days
for MSCs from BM, AT and UC and was confirmed by the
deposition of a hyaline matrix rich in proteoglycans. The
Alcian Blue (blue areas) and toluidine blue staining (meta-
chromatic pink areas) (Figure 2) were performed, which
identified an extracellular matrix rich in proteoglycans.Immunophenotypic characterization
Immunophenotypic analysis at P3 of BM-MSCs, AT-MSCs
and UC-MSCs by flow cytometry revealed MSCs with a
high expression of CD90, CD105 and CD44 markers and
a low or absent expression of CD34 and MHC II markers
(Figure 3). A minimum of 10,000 cells were used for flow
cytometry evaluation. The average percentage with stand-
ard deviation for each marker from the different sources
of MSCs can be observed in Table 1.
MSCs from BM, AT and UC showed no expression of
MHC-II as assessed by immunocytochemistry techniques
(Figure 4).Discussion
Several sources have been studied for obtaining equine
MSCs, such as bone marrow [34], adipose tissue [11],
umbilical cord blood [8], umbilical cord tissue [36], am-
niotic membrane [13], peripheral blood [37], tendon [27]
and amniotic fluid [23]. Bone marrow and adipose tissue
are the most studied sources [9,12,21,38], but recent
studies are using cells from other sources, such as fetal
tissues [15,31,39], because these samples can be obtained
non-invasively and they are easily accessible, abundant
and easy to collect [22,23].
Bone marrow puncture requires a qualified profes-
sional, can be painful and is an invasive technique with
the risk of thoracic puncture [13,40], but it is a quick
method of harvest and causes less site injury than adi-
pose tissue harvest [28], although there are minimally in-
vasive methods described to harvest adipose tissue, such
as liposuction [41].
Adipose tissue has advantages over BM, such as an
abundance in the body, ease of collection and the ability
to culture a larger number of cells with better quality
[9,42]. However, it can be difficult to collect AT samples
from lean horses [29,40].
In humans, fetal cells have advantages over adult cells
because they can proliferate faster in vitro, have low
levels of histocompatibility antigens and can survive at
lower oxygen tensions, making them more resistant to
hypoxia during transplantation [14]. However, as observed
Figure 2 Differentiation potential of MSCs from equine BM, AT and UC. Differentiation of MSCs from BM (A, D, G, J), AT (B, E, H, K) and UC
(C, F, I, L) into three mesenchymal lineages during the third passage. (A-C) MSCs showing intracytoplasmic lipid droplets confirming the adipogenic
lineage. (D-F) MSCs stained with Alizarin Red showing matrix calcium formation. (G-L) MSCs after chondrogenic differentiation stained with Alcian Blue
(G-I) and toluidine blue (J-L) showing hyaline matrix. 100x (D-L), 200x (B) and 400x (A, C) magnification. AT, adipose tissue; BM, bone marrow; MSCs,
mesenchymal stem cells; UC, umbilical cord.
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as those in adipose tissue [23].
Stem cells from the umbilical cord (UC) of horses can
be isolated from umbilical cord tissue (UCT), Wharton’s
jelly or from the umbilical cord blood (UCB). The tech-
nique for collection is minimally invasive and can be
performed without harm to the foal or mare [36,43].
In the present study, BM, AT and UC were used as
sources for obtaining equine MSCs, and the MSCs’
expression of surface markers and their differentiation
potential into osteogenic, adipogenic and chondrogenic
lineages were evaluated to compare these sources for an
allogeneic therapy cell bank. All stages of this study were
performed during the third passage because the cells
reached homogeneous culture at this point, as observed
in other studies [21,44,45].
MSC differentiation into osteogenic, adipogenic and
chondrogenic mesodermal lineages is an importantfeature that should always be used to verify the multi-
potentiality of MSCs [22], so in this study, BM-MSCs,
AT-MSCs and UC-MSCs underwent differentiation
into mesodermal lineages to prove the differentiation
potential of MSCs from each of the sources studied as
postulated by Dominici et al. [25].
The BM-MSCs and AT-MSCs differentiated within
10 days into the osteogenic lineage and within 8 days
into the adipogenic lineage. This time period is in agree-
ment with other studies with MSCs from BM and AT,
where they differentiated within 7 to 15 days into the
adipogenic lineage and within 7 to 18 days into the
osteogenic lineage [21,27,46].
The UC-MSCs used in this study did not differentiate
into these lineages in the same time period; the osteo-
genic and adipogenic differentiation occurred only after
15 days. This longer time period required for diffe-
rentiation has been reported in other studies, where
Figure 3 (See legend on next page.)
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Figure 3 Expression of cell surface markers by flow cytometry of MSCs from BM, AT and UC. Histograms representing the profile of BM-MSC,
AT-MSC and UC-MSC samples analyzed using flow cytometry during the third passage, evaluating the cell surface markers CD90, CD44, CD105, CD34
and MHC-II. MSCs were positive for CD90, CD44 and CD105, were negative for CD34 and showed low expression of MHC-II. AT, adipose tissue; BM,
bone marrow; MSCs, mesenchymal stem cells; UC, umbilical cord.
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[22,23] and adipogenic differentiation within 25 days
[23]. However, Corradetti et al. [35] reported an osteo-
genic differentiation of UCT in just 10 days. Toupadakis
et al. [40] reported that the addition of 20% fetal calf
serum (FCS) induces faster and more efficient osteo-
genic differentiation.
Despite the difference in the time required for cell differ-
entiation among the sources, there were no differences in
the differentiation potential of BM-MSCs, AT-MSCs and
UC-MSCs because all cells were able to differentiate into
the three mesodermal lineages. Nevertheless, studies have
reported that osteogenic differentiation of MSCs is better
in BM-MSCs and that chondrogenic differentiation can be
better in UC-MSCs [23,27] or BM-MSCs [40,46]. More-
over, MSCs from an equine umbilical cord matrix may be
able to differentiate into neuronal cells in addition to these
three lineages [22].
Due to the lack of specific equine antibodies and the low
reactivity of markers from other species to equine species
[11,17], different markers have been tested and used. In the
present study, the CD90, CD34, CD44, CD105 and MHC-
II markers were used, taking into account some of the cri-
teria established by the International Society for Cellular
Therapy for the characterization of human MSCs [25] and
adipose tissue-derived stromal/stem cells [26], as well as
other studies with equine MSCs that already used some of
these markers [20,21,23,24,45,47]. Additionally, it has been
shown that human AT-MSCs can be distinguished from
BM-MSCs by their positivity for CD36 and negativity for
CD106 [26], but it is not determined in equine MSCs.
The MSCs from BM, AT and UC under the culture
conditions utilized showed high positivity for CD90,Table 1 Percentage means of the immunophenotypic
characterization of BM-MSCs, AT-MSCs and UC-MSCs by
flow cytometry
Source Marker
CD105 CD90 CD44 CD34 MHC-II
UC 94.2 ± 2.1 67.7 ± 6.5a 95.7 ± 1.5 0.20 ± 0.3a 5.9 ± 1.8
BM 97.7 ± 2.3 98.2 ± 7.1b 96.2 ± 1.6 0.28 ± 0.3a 6.8 ± 2.0
AT 94.2 ± 2.3 99.2 ± 7.1b 92.4 ± 1.6 1.21 ± 0.3b 3.8 ± 2.0
P-value 0.5442 0.0033 0.1994 0.0197 0.4896
Percentage means of MSCs from BM, AT and UC during the third passage for
the CD90, CD105, CD44, CD34 and MHC-II markers by flow cytometry. AT,
adipose tissue; BM, bone marrow; MSCs, mesenchymal stem cells; UC,
umbilical cord.
a,bOverrides different letters in the same column that differ (P <0.05).CD44 and CD105, were negative for CD34 and showed
low expression of MHC-II.
Several studies with equine MSCs also showed high
expression of CD90 (82 to 93%), CD44 (79 to 98%) and
CD105 (78 to 93%) [16,20,23,44,48]. However, Xie et al.
[45] demonstrated the lowest expression of CD 105 (64%)
in BM samples, and De Schauwer et al. [24] observed a
large variation of CD105 expression (0, 1 to 20%) among
UCB samples, and another study with UCT [35] reported
negative expression of CD105, possibly because the anti-
body did not work for the cells studied.
In the present study, UC-MSCs showed lower expres-
sion of the CD90 marker (mean 67.7%) when compared
with the BM-MSCs and AT-MSCs, unlike other studies
[43,44,49] where the expression was higher. However, a
study [50] with amniotic fluid demonstrated that the
CD90 marker decreases as pregnancy develops. This in-
verse relationship may explain the findings in this present
study because the samples collected in the slaughterhouse
were from the final months of gestation (9 to 10 months).
Studies using AT-MSCs [12,21] reported increased
CD34 expression compared to BM-MSCs; however, this
expression was higher than that obtained in the present
study (mean 1.1%).
The differences between animals may be due to labor-
atorial procedures and the biological differences between
the donors because the species, age, gender and site of
collection may influence the number, phenotype and
in vitro biological characteristics of the MSCs [16].
The MHC-II expression in BM-MSCs, AT-MSCs and
UC-MSCs did not show significant differences, revealing
low expression for all samples. This result is similar to a
study of MSCs from UCB, which also showed low ex-
pression of MHC-II (8%) [24]. However, AT-MSCs had
the lowest expression (3.8% on average) of MHC-II,
which would result in a reduced risk of immune reaction
against allogeneic therapy. In several other studies, the
expression of MHC-II was negative by flow cytometry
[20,22] and RT-PCR [23,35] techniques. Expression was
observed in the present study only by the immunocyto-
chemistry technique. Therefore, more studies should be
performed to better characterize the low expression or
lack of expression of MHC-II in several cellular sources
from horses.
The bone marrow and adipose tissues were the best
cell sources for obtaining MSCs under the in vitro con-
ditions used because they differentiated in a faster time
and showed higher cell growth than umbilical cord.
Figure 4 Evaluation of MHC-II expression in MSCs from BM, AT
and UC using the immunocytochemistry technique.
Immunocytochemistry of MSCs from equine BM (A), AT (B) and UC
(C) during the third passage to evaluate the expression of the MHC-II
cell surface marker. MSCs from the sources analyzed did not express
MHC-II. 200x (A, B) and 100x (C) magnification. AT, adipose tissue; BM,
bone marrow; MSCs, mesenchymal stem cells; UC, umbilical cord.
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able and reliable source of MSCs for cell therapy in the
horse when compared with peripheral blood. In vitro
studies demonstrated that BM-MSCs have better cell dif-
ferentiation potential than AT-MSCs, suggesting thatthey are a superior source of cells for the musculoskel-
etal regeneration of horses, but this difference has not
yet been shown in vivo [9]. Additionally, when compar-
ing BM with UCB [14], MSCs from BM have more mes-
enchymal progenitor cells. The proliferation and
differentiation capacities of BM-MSCs are inversely pro-
portional to the age of the donors and the number of
passages in cell culture [13,21].
In our study, AT-MSCs showed the highest cell growth
until the third passage, corroborating with studies com-
paring BM and AT as sources of MSCs and reporting that
AT has a larger amount of MSCs with a higher potential
for proliferation [18,27,38,42], which would make adipose
tissue an advantageous source for allogeneic bank cre-
ation. Even after cryopreservation, they retain their prolif-
erative potential and differentiation capacity [51].
On the other hand, studies with MSCs from UCB [14,30]
describe some advantages over BM cells: they are less
immunogenic, they cause less graft versus host disease,
their collection is noninvasive, they have a higher prolifer-
ative rate, they have a higher number of cells per volume
collected, and their ability to be cryopreserved generates a
ready-to-use product.
Despite our findings, further studies are required to as-
sess changes in the differentiation potential of BM-MSCs,
AT-MSCs and UC-MSCs at the higher passages, as well as
to elucidate biological mechanisms involved in therapeutic
potential and senescence comparing several sources for
equine MSCs. There is still no consensus on what would
be the best source for obtaining these cells for cell bank
and clinical purposes due to the conflicting results among
studies.Conclusions
Equine BM, AT and UC are viable sources for obtaining
MSCs based on the principles established by the ISCT, as
this study confirmed the immunophenotypic and multipo-
tentiality characteristics of these cells. Based on the low
expression of MHC-II, BM-MSCs, AT-MSCs and UC-
MSCs could be used in clinical trials involving allogeneic
therapy in horses. Under the experimental conditions of
this study, the BM-MSCs and AT-MSCs showed fastest
in vitro differentiation and AT-MSCs showed highest cell
growth until the third passage. These findings suggest that
BM and AT may be preferable for cell banking purposes.Abbreviations
AT: Adipose tissue; AT-MSCs: Mesenchymal stem cells from adipose tissue;
BM: Bone marrow; BM-MSCs: Mesenchymal stem cells from bone marrow;
DMEM: Dulbecco’s Modified Eagle Medium; HBSS: Hanks’ Balanced Salt
Solution; ISCT: International Society for Cellular Therapy; LSD: Least significant
difference; MHC-II: Major histocompatibility complex class II;
MSCs: Mesenchymal stem cells; P3: Third passage; UC: Umbilical cord;
UCB: Umbilical cord blood; UC-MSCs: Mesenchymal stem cells from umbilical
cord; UCT: Umbilical cord tissue.
Barberini et al. Stem Cell Research & Therapy 2014, 5:25 Page 10 of 11
http://stemcellres.com/content/5/1/25Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DJB was responsible for the conception and design of the study, data
collection and analysis of BM, AT and UC-MSCs, labelling of MSCs for flow cy-
tometry, immunocytochemistry and cell differentiation, manuscript writing
and giving final approval of the manuscript. NPPF assisted with collections of
AT, participated in the isolation and cultivation of AT-MSCs and assisted in
the preparation of MSCs for flow cytometry. MSM performed the analysis
and interpretation of data from flow cytometry of AT-MSCs and UC-MSCs.
LM participated in the collection, isolation and culture of BM-MSCs and
assisted in immunocytochemistry and cellular differentiation experiments.
AJL participated in the isolation and culture of BM-MSCs and assisted with
the cell differentiation staining. MCH participated in the collections of BM
and assisted in the isolation and culture of UC-MSCs. MJS performed the
statistical analysis and interpreted the data. MAG performed the analysis and
interpretation of BM-MSC flow cytometry data. FCLA was responsible for
supervision of the isolation and culture of MSCs in the laboratory. RMA
contributed to the conception and coordination of the study, participated in
the collection of samples from BM, manuscript writing and final approval of
the manuscript. All authors read and approved the final manuscript.
Acknowledgements
This study was funded by FUNDUNESP (Foundation for the development of
UNESP) and CNPq (National Council for Scientific and Technological
Development). The authors thank FAPESP (Foundation for Research Support
of the State of São Paulo) for the Master scholarship during the
development of the study. The funding agencies played no role in the
development of the study, collection, analysis and interpretation of the data,
in the writing of the manuscript, or in the decision to submit the manuscript
for publication. The authors thank the veterinarian Dr. Campo Amor for his
help in the collection of umbilical cord samples.
Author details
1Departament of Veterinary Clinics, College of Veterinary Medicine and
Animal Science, São Paulo State University, UNESP, Botucatu, SP, Brazil.
2Hemocenter Division of Botucatu Medical School, São Paulo State
University, UNESP, Botucatu, SP, Brazil. 3General and Applied Biology,
Botucatu Biosciences Institute, São Paulo State University, UNESP, Botucatu,
SP, Brazil. 4Laboratory of Genetics and Animal Breeding, Federal University of
Pampa, Uruguaiana, RS, Brazil. 5Department of Animal Reproduction and
Veterinary Radiology, College of Veterinary Medicine and Animal Science,
São Paulo State University, UNESP, Botucatu, SP, Brazil.
Received: 1 August 2013 Revised: 21 November 2013
Accepted: 13 February 2014 Published: 21 February 2014
References
1. Chamberlain G, Fox J, Ashton B, Middleton J: Concise review:
mesenchymal stem cells: their phenotype, differentiation capacity,
immunological features, and potential for homing. Stem Cells 2007,
25:2739–2749.
2. Nöth U, Rackwitz L, Steinert AF, Tuan RS: Cell delivery therapeutics for
musculoskeletal regeneration. Adv Drug Deliv Rev 2010, 62:765–783.
3. Taylor SE, Smith RK, Clegg PD: Mesenchymal stem cell therapy in equine
musculoskeletal disease: scientific fact or clinical fiction? Equine Vet J
2007, 39:172–180.
4. Guest DJ, Smith MR, Allen WR: Monitoring the fate of autologous and
allogeneic mesenchymal progenitor cells injected into the superficial
digital flexor tendon of horse: preliminary study. Equine Vet J 2008,
40:178–181.
5. Carrade DD, Owens SD, Galuppo LD, Vidal MA, Ferraro GL, Librach F,
Buerchler S, Friedman MS, Walker NJ, Borjesson DL: Clinicopathologic
findings following intra-articular injection of autologous and allogeneic
placentally derived equine mesenchymal stem cells in horses.
Cytotherapy 2011, 13:419–430.
6. Chen Y, Shao JZ, Xiang LX, Dong XJ, Zhang GR: Mesenchymal stem cells: a
promising candidate in regenerative medicine. Int J Biochem Cell Biol
2008, 40:815–820.7. Wu X, Tao R: Hepatocyte differentiation of mesenchymal stem cells.
Hepatobiliary Pancreat Dis Int 2012, 11:360–371.
8. Reed SA, Johnson SE: Equine umbilical cord blood contains a population
of stem cells that express Oct4 and differentiate into mesodermal and
endodermal cell types. J Cell Physiol 2008, 215:329–336.
9. Gutierrez-Nibeyro SD: Commercial cell-based therapies for musculoskeletal
injuries in horses. Vet Clin North Am Equine Pract 2011, 27:363–371.
10. Sole A, Spriet M, Galuppo LD, Padgett KA, Borjesson DL, Wisner ER, Brosnan
RJ, Vidal MA: Scintigraphic evaluation of intra-arterial and intravenous
regional limb perfusion of allogeneic bone marrow-derived
mesenchymal stem cells in the normal equine distal limb using (99 m)
Tc-HMPAO. Equine Vet J 2012, 44:594–599.
11. Carvalho AM, Alves AL, Golim MA, Moroz A, Hussni CA, Oliveira PG, Deffune
E: Isolation and immunophenotypic characterization of mesenchymal
stem cells derived from equine species adipose tissue. Vet Immunol
Immunopathol 2009, 132:303–306.
12. Ranera B, Lyahyaia J, Romero A, Vázquez FJ, Remacha AR, Bernal ML,
Zaragoza P, Rodellar C, Martín-Burriel I: Immunophenotype and gene
expression profiles of cell surface markers of mesenchymal stem cells
derived from equine bone marrow and adipose tissue. Vet Immunol
Immunopathol 2011, 144:147–154.
13. Lange-Consiglio A, Corradetti B, Meucci A, Perego R, Bizzaro D, Cremonesi F:
Characteristics of equine mesenchymal stem cells derived from amnion
and bone marrow: in vitro proliferative and multilineage potential
assessment. Equine Vet J 2013, 45:737–744.
14. Rogers I, Casper RF: Umbilical cord blood stem cells. Best Pract Res Clin
Obstet Gynaecol 2004, 18:893–908.
15. Guest DJ, Ousey JC, Smith MR: Defining the expression of marker genes
in equine mesenchymal stromal cells. Stem Cells Cloning 2008, 1:1–9.
16. Pascuccia L, Curinab G, Mercatia F, Marinib C, Dall’Aglio C, Paternesi B,
Ceccarelli P: Flow cytometric characterization of culture expanded
multipotent mesenchymal stromal cells (MSCs) from horse adipose
tissue: towards the definition of minimal stemness criteria. Vet Immunol
Immunopathol 2011, 144:499–506.
17. De Schauwer C, Meyer E, Van de Walle GR, Van Soom A: Markers of
stemness in equine mesenchymal stem cells: a plea for uniformity.
Theriogenology 2010, 75:1431–1443.
18. Borjesson DL, Peroni JF: The regenerative medicine laboratory: facilitating
stem cell therapy for equine disease. Clin Lab Med 2011, 31:109–123.
19. Burk J, Badylak SF, Kelly J, Brehm W: Equine cellular therapy – from stall to
bench to bedside? Cytometry A 2013, 83:103–113.
20. Carrade DD, Lame MW, Kent MS, Clark KC, Walker NJ, Borjesson DL:
Comparative analysis of the immunomodulatory properties of equine
adult-derived mesenchymal stem cells. Cell Med 2012, 4:1–11.
21. Ranera B, Ordovás L, Lyahyai J, Bernal ML, Fernandes F, Remacha AR,
Romero A, Vázquez FJ, Osta R, Cons C, Varona L, Zaragoza P,
Martín-Burriel I, Rodellar C: Comparative study of equine bone marrow
and adipose tissue-derived mesenchymal stromal cells. Equine Vet J
2012, 44:33–42.
22. Hoynowski SM, Fry MM, Gardner BM, Leming MT, Tucker JR, Black L, Sand T,
Mitchell KE: Characterization and differentiation of equine umbilical
cord-derived matrix cells. Biochem Biophys Res Commun 2007, 362:347–353.
23. Lovati AB, Corradetti B, Lange Consiglio A, Recordati C, Bonacina E, Bizzaro
D, Cremonesi F: Comparison of equine bone marrow-, umbilical cord
matrix and amniotic fluid-derived progenitor cells. Vet Res Commun 2011,
35:103–121.
24. De Schauwer C, Piepers S, Van de Walle GR, Demeyere K, Hoogewijs MK,
Govaere JL, Braeckmans K, Van Soom A, Meyer E: In search for cross-reactivity
to immunophenotype equine mesenchymal stromal cells by multicolor
flow cytometry. Cytometry A 2012, 81A:312–323.
25. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS,
Deans RJ, Keating A, Prockop DJ, Horwitz EM: Minimal criteria for defining
multipotent mesenchymal stromal cells. The International Society for
cellular therapy position statement. Cytotherapy 2006, 8:315–317.
26. Bourin P, Bunnell BA, Casteilla L, Dominici M, Katz AJ, March KL, Redl H,
Rubin JP, Yoshimura K, Gimble JM: Stromal cells from the adipose
tissue-derived stromal vascular fraction and culture expanded
adipose tissue-derived stromal/stem cells: a joint statement of the
International Federation for Adipose Therapeutics and Science (IFATS)
and the International Society for Cellular Therapy (ISCT). Cytotherapy
2013, 15:641–648.
Barberini et al. Stem Cell Research & Therapy 2014, 5:25 Page 11 of 11
http://stemcellres.com/content/5/1/2527. Burk J, Ribitsch I, Gittel C, Juelke H, Kasper C, Staszyk C, Brehm W: Growth
and differentiation characteristics of equine mesenchymal stromal cells
derived from different sources. Vet J 2013, 195:98–106.
28. Richardson LE, Dudhia J, Clegg PD, Smith R: Stem cells in veterinary
medicine – attempts at regenerating equine tendon after injury. Trends
Biotechnol 2007, 25:409–416.
29. Nixon AJ, Dahlgren LA, Haupt JL, Yeager AE, Ward DL: Effect of adipose-derived
nucleated cell fractions on tendon repair in horses with collagenase-induced
tendinitis. Am J Vet Res 2008, 69:928–937.
30. Kern S, Eichler H, Stoeve J, Klüter H, Bieback K: Comparative analysis of
mesenchymal stem cells from bone marrow, umbilical cord blood, or
adipose tissue. Stem Cells 2006, 24:1294–1301.
31. Carrade DD, Affolter VK, Outerbridge CA, Watson JL, Galuppo LD, Buerchler
S, Kumar V, Walker NJ, Borjesson DL: Intradermal injections of equine
allogeneic umbilical cord-derived mesenchymal stem cells are well
tolerated and do not elicit immediate or delayed hypersensitivity
reactions. Cytotherapy 2011, 13:1180–1192.
32. Peroni JF, Borjesson DL: Anti-inflammatory and immunomodulatory
activities of stem cells. Vet Clin North Am Equine Pract 2011, 27:351–362.
33. Ryan JM, Barry FP, Murphy JM, Mahon BP: Mesenchymal stem cells avoid
allogeneic rejection. J Inflamm (Lond) 2005, 2:8.
34. Maia L, Landim-Alvarenga FC, Da Mota LS, De Assis Golim M, Laufer-Amorim R,
De Vita B, Barberini DJ, Listoni AJ, De Moraes CN, Heckler MC, Amorim RM:
Immunophenotypic, immunocytochemistry, ultrastructural, and cytogenetic
characterization of mesenchymal stem cells from equine bone marrow.
Microsc Res Tech 2013, 76:618–624.
35. Corradetti B, Lange-Consiglio A, Barucca M, Cremonesi F, Bizzaro D: Size-sieved
subpopulations of mesenchymal stem cells from intervascular and
perivascular equine umbilical cord matrix. Cell Prolif 2011, 44:330–342.
36. Bartholomew S, Owens SD, Ferraro GL, Carrade DD, Lara DJ, Librach FA,
Borjesson DL, Galuppo LD: Collection of equine cord blood and placental
tissues in 40 thoroughbred mares. Equine Vet J 2009, 41:724–728.
37. Koerner J, Nesic D, Romero JD, Brehm W, Mainil-Varlet P, Grogan SP: Equine
peripheral blood-derived progenitors in comparison to bone marrow-
derived mesenchymal stem cells. Stem Cells 2006, 24:1613–1619.
38. Colleoni S, Bottani E, Tessaro I, Mari G, Merlo B, Romagnoli N, Spadari A,
Galli C, Lazzari G: Isolation, growth and differentiation of equine
mesenchymal stem cells: effect of donor, source, amount of tissue and
supplementation with basic fibroblast growth factor. Vet Res Commun
2009, 33:811–821.
39. Vidal MA, Walker NJ, Napoli E, Borjesson DL: Evaluation of senescence in
mesenchymal stem cells isolated from equine bone marrow, adipose
tissue, and umbilical cord tissue. Stem Cells Dev 2012, 21:273–283.
40. Toupadakis CA, Wong A, Genetos DC, Cheung WK, Borjesson DL, Ferraro GL,
Galuppo LD, Leach JK, Owens SD, Yellowley CE: Comparison of the
osteogenic potential of equine mesenchymal stem cells from bone
marrow, adipose tissue, umbilical cord blood, and umbilical cord tissue.
Am J Vet Res 2010, 71:1237–1245.
41. Raabe O, Reich C, Wenisch S, Hild A, Burg-Roderfeld M, Siebert HC, Arnhold
S: Hydrolyzed fish collagen induced chondrogenic differentiation of
equine adipose tissue-derived stromal cells. Histochem Cell Biol 2010,
134:545–554.
42. Vidal MA, Kilroy GE, Lopez MJ, Johnson JR, Moore RM, Gimble JM:
Characterization of equine adipose tissue-derived stromal cells:
adipogenic and osteogenic capacity and comparison with bone
marrow-derived mesenchymal stromal cells. Vet Surg 2007, 36:613–622.
43. Troyer DL, Weiss ML: Concise review: Wharton’s jelly-derived cells are a
primitive stromal cell population. Stem Cells 2008, 26:591–599.
44. Iacono E, Brunori L, Pirrone A, Pagliaro PP, Ricci F, Tazzari PL, Merlo B:
Isolation, characterization and differentiation of mesenchymal stem cells
from amniotic fluid, umbilical cord blood and Wharton’s jelly in the
horse. Reproduction 2012, 143:455–468.
45. Xie L, Zhang N, Marsano A, Vunjak-Novakovic G, Zhang Y, Lopez MJ: In vitro
mesenchymal trilineage differentiation and extracellular matrix production
by adipose and bone marrow derived adult equine multipotent stromal
cells on a collagen scaffold. Stem Cell Rev 2013, 9:858–872.
46. Vidal MA, Robinson SO, Lopez MJ, Paulsen DB, Borkhsenious O, Johnson JR,
Moore RM, Gimble JM: Comparison of chondrogenic potential in equine
mesenchymal stromal cells derived from adipose tissue and bone
marrow. Vet Surg 2008, 37:713–724.47. Radcliffe CH, Flaminio MJ, Fortier LA: Temporal analysis of equine bone
marrow aspirate during establishment of putative mesenchymal
progenitor cell populations. Stem Cells Dev 2010, 19:269–281.
48. Braun J, Hack A, Weis-Klemm M, Conrad S, Treml S, Kohler K, Walliser U,
Skutella T, Aicher WK: Evaluation of the osteogenic and chondrogenic
differentiation capacities of equine adipose tissue–derived mesenchymal
stem cells. Am J Vet Res 2010, 71:1228–1236.
49. Secco M, Zucconi E, Vieira NM, Fogaça LL, Cerqueira A, Carvalho MD,
Jazedje T, Okamoto OK, Muotri AR, Zatz M: Multipotent stem cells from
umbilical cord: cord is richer than blood! Stem Cells 2008, 26:146–150.
50. De Vita B, Campos LL, Listoni AJ, Maia L, Sudano MJ, Curcio BR, Landim-
Alvarenga FC, Prestes NC: Isolamento, caracterização ediferenciação de
células-tronco mesenquimais do líquido amniótico equino obtido em
diferentes idades gestacionais. Pesq Vet Bras 2013, 33:535–542.
51. Mambelli LI, Santos EJ, Frazão PJ, Chaparro MB, Kerkis A, Zoppa AL, Kerkis I:
Characterization of equine adipose tissue-derived progenitor cells before
and after cryopreservation. Tissue Eng Part C Methods 2009, 15:87–94.
doi:10.1186/scrt414
Cite this article as: Barberini et al.: Equine mesenchymal stem cells from
bone marrow, adipose tissue and umbilical cord: immunophenotypic
characterization and differentiation potential. Stem Cell Research &
Therapy 2014 5:25.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
